Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
This review summarizes recent advances in rheumatoid arthritis biology and therapy, highlighting precision medicine opportunities, safety concerns, and persistent unmet clinical needs.
This article reviews PCSK9’s pleiotropic biology beyond LDLR, evaluating inflammation, Lp(a), apoB metabolism, and emerging therapies with translational evidence.
A recent perspective debates whether additional TKIs are still needed in CML, arguing that despite major progress, ongoing issues with resistance, intolerance, and optimal sequencing leave room for further innovation.
Mechanistically diverse MASLD/MASH therapies show strong histologic signals but uncertain clinical translation, limited by fibrosis biology, tolerability, and biomarker gaps
An integrated pre-LOE playbook aligning clinical, regulatory, commercial, and financial levers can mitigate erosion and preserve oncology franchise value amid biosimilar entry.
Recent Chinese and US hypertension guidelines converge on intensive treatment targets and core first-line therapies, yet diverge in diagnostic thresholds and pharmacotherapy initiation for low-risk stage 1 hypertension.
Feb 2025–Feb 2026 oncology deals favored fewer, larger transactions: milestone-heavy early licenses, mostly upfront M&A, modality innovation, rising China out-licensing.
GalNAc-targeted siRNA/ASO therapies enable durable hepatocyte gene silencing of metabolic regulators, improving lipids/NASH targets with infrequent dosing and ongoing outcomes validation.
This review summarizes irAE pathogenesis and organ-specific diagnosis and management, emphasizing early recognition, guideline-based immunosuppression, and multidisciplinary care.
Urothelial carcinoma therapy is rapidly evolving, with biomarker-driven combinations redefining survival and precision sequencing across disease stages.
A practical FUO approach starts with careful history, basic labs, and targeted tests, escalates to imaging and biopsy when needed, and avoids common pitfalls like premature empiric therapy and over-reliance on imaging without tissue confirmation.
Radiopharmaceutical therapeutics are becoming an increasingly important oncology sector, shaped by growing pipelines and emerging alpha-emitter innovation despite supply constraints.
EGFR therapies evolved through multiple generations to 2026, transforming major cancers, while this review summarizes resistance, diagnostics, and six future priorities.
A comprehensive review summarizes 2021–2026 advances showing how genetic, environmental, immune, and microbial factors drive CD and UC pathogenesis, while highlighting ongoing refractory disease and the need for precision-medicine translation.
The gut microbiome is increasingly linked to metabolic disease, but clinical translation remains early and inconsistent.
A concise overview of how ADCs have evolved clinically and technologically, highlighting pivotal approvals, resistance mechanisms and emerging strategies such as novel payloads, smarter linkers, and combination regimens.
A clinician-focused overview of approved Pompe disease ERTs, summarizing key trial evidence, real-world outcomes and treatment strategies across infantile- and late-onset disease.
Semaglutide offers substantial clinical benefits, yet understanding how to monitor and manage adverse effects is key to safe use.
This review outlines the epidemiology and evidence-based management of menopausal vasomotor symptoms, emphasizing individualized treatment and emerging nonhormonal options.
This review summarizes current treatments and emerging drug development strategies in schizophrenia.